Index RUT
P/E -
EPS (ttm) -8.40
Insider Own 18.39%
Shs Outstand 60.04M
Perf Week -14.63%
Market Cap 716.14M
Forward P/E -
EPS next Y -5.04
Insider Trans 0.00%
Shs Float 49.11M
Perf Month -28.18%
Income -503.14M
PEG -
EPS next Q -1.66
Inst Own 92.74%
Short Float 16.60%
Perf Quarter -49.77%
Sales 91.06M
P/S 7.86
EPS this Y 28.60%
Inst Trans 0.73%
Short Ratio 7.63
Perf Half Y -35.68%
Book/sh 11.73
P/B 1.01
EPS next Y 22.02%
ROA -50.61%
Short Interest 8.15M
Perf Year -77.39%
Cash/sh 11.94
P/C 1.00
EPS next 5Y 16.80%
ROE -54.72%
52W Range 10.92 - 59.99
Perf YTD -45.09%
Dividend Est. -
P/FCF -
EPS past 5Y -2.28%
ROI -71.29%
52W High -80.16%
Beta 0.95
Dividend TTM -
Quick Ratio 12.22
Sales past 5Y 3395.58%
Gross Margin 96.12%
52W Low 8.97%
ATR (14) 0.89
Dividend Ex-Date -
Current Ratio 12.22
EPS Y/Y TTM 10.43%
Oper. Margin -557.93%
RSI (14) 29.55
Volatility 5.23% 6.83%
Employees 487
Debt/Eq 0.00
Sales Y/Y TTM 868.87%
Profit Margin -552.52%
Recom 2.67
Target Price 22.24
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 26.68%
Payout -
Rel Volume 0.65
Prev Close 12.34
Sales Surprise 50.21%
EPS Surprise -9.16%
Sales Q/Q 139.89%
Earnings Apr 25 BMO
Avg Volume 1.07M
Price 11.90
SMA20 -12.45%
SMA50 -29.90%
SMA200 -42.78%
Trades
Volume 697,973
Change -3.57%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-17-24 Downgrade
BofA Securities
Neutral → Underperform
$24 → $14
Dec-12-23 Initiated
Deutsche Bank
Hold
$21
Aug-08-23 Downgrade
Needham
Buy → Hold
Aug-08-23 Downgrade
Goldman
Buy → Neutral
$22
Aug-08-23 Downgrade
Canaccord Genuity
Buy → Hold
$64 → $21
Aug-07-23 Downgrade
Wedbush
Outperform → Neutral
$51 → $22
Aug-07-23 Downgrade
Stifel
Buy → Hold
$60 → $22
Aug-07-23 Downgrade
RBC Capital Mkts
Outperform → Sector Perform
$71 → $25
Aug-07-23 Downgrade
Oppenheimer
Outperform → Perform
Aug-07-23 Downgrade
BofA Securities
Buy → Neutral
$66 → $25
Jul-27-23 Initiated
Scotiabank
Sector Outperform
Mar-13-23 Upgrade
RBC Capital Mkts
Sector Perform → Outperform
$40 → $60
Jan-03-23 Downgrade
Guggenheim
Buy → Neutral
Nov-01-22 Initiated
Loop Capital
Hold
$41
Mar-31-22 Initiated
Berenberg
Hold
$37
Nov-02-21 Upgrade
Guggenheim
Neutral → Buy
$55
Oct-19-21 Resumed
Morgan Stanley
Equal-Weight
$78 → $66
Oct-07-21 Downgrade
Jefferies
Buy → Hold
$100 → $50
Sep-23-21 Initiated
Needham
Buy
$84
Jun-16-21 Downgrade
Citigroup
Buy → Neutral
$101 → $68
Show Previous Ratings
May-07-24 06:30AM
Apr-30-24 12:57PM
Apr-26-24 11:27AM
Apr-25-24 02:33PM
10:54AM
08:04AM
Loading…
08:04AM
07:35AM
06:30AM
Apr-18-24 11:37AM
10:01AM
Apr-17-24 04:10PM
(Investor's Business Daily) -19.58%
02:41PM
08:46AM
(Investor's Business Daily)
07:44AM
06:39AM
06:30AM
Loading…
06:30AM
Apr-11-24 07:29PM
06:30AM
Apr-10-24 06:09PM
07:47AM
Mar-18-24 10:16AM
Mar-15-24 11:30AM
Feb-28-24 06:30AM
Feb-15-24 01:36PM
10:50AM
Feb-14-24 07:15AM
06:42AM
06:30AM
Feb-07-24 10:00AM
Jan-31-24 06:30AM
06:32AM
Loading…
Jan-08-24 06:32AM
06:30AM
Jan-02-24 06:30AM
Dec-20-23 02:15PM
Dec-14-23 06:30AM
Dec-07-23 11:31AM
Nov-13-23 11:13AM
Nov-08-23 01:11PM
07:59AM
06:30AM
Nov-07-23 06:02PM
05:41PM
12:40PM
08:44AM
07:40AM
07:21AM
06:30AM
06:30AM
Nov-02-23 10:00AM
Oct-31-23 10:01AM
Oct-24-23 06:42AM
06:30AM
Oct-19-23 12:16PM
Oct-18-23 06:30AM
Oct-14-23 01:14PM
Sep-15-23 03:01PM
(American City Business Journals)
Sep-13-23 04:43PM
(American City Business Journals)
Sep-06-23 02:27PM
06:30AM
Sep-01-23 03:51PM
(Investor's Business Daily)
01:27PM
Aug-31-23 11:10AM
(Investor's Business Daily)
10:10AM
(American City Business Journals)
09:36AM
07:00AM
06:44AM
06:40AM
06:30AM
Aug-24-23 10:23AM
05:10AM
Aug-11-23 12:05PM
11:23AM
10:34AM
08:50AM
Aug-08-23 09:42AM
09:00AM
06:02AM
Aug-07-23 04:06PM
(Investor's Business Daily) -53.60%
03:50PM
11:58AM
11:44AM
10:32AM
(American City Business Journals)
10:32AM
(American City Business Journals)
10:14AM
10:04AM
09:57AM
09:57AM
08:09AM
08:06AM
07:40AM
06:30AM
Aug-04-23 10:45PM
10:42PM
08:44PM
(American City Business Journals)
08:13PM
07:24PM
(The Wall Street Journal)
07:13PM
07:11PM
Jul-29-23 11:39AM
Jul-26-23 03:46PM
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
IGUCHI KIMI CFO & Treasurer Jan 02 '24 Option Exercise 1.36 1,642 2,233 70,429 Jan 04 04:07 PM Barrett Elizabeth Director Aug 09 '23 Buy 18.64 2,000 37,279 3,000 Aug 11 08:51 AM
Index -
P/E -
EPS (ttm) -1.93
Insider Own 13.61%
Shs Outstand 47.26M
Perf Week -3.34%
Market Cap 495.47M
Forward P/E -
EPS next Y -1.61
Insider Trans -0.63%
Shs Float 41.08M
Perf Month 8.43%
Income -85.08M
PEG -
EPS next Q -0.41
Inst Own 57.90%
Short Float 4.26%
Perf Quarter 14.07%
Sales 2.71M
P/S 182.83
EPS this Y 22.77%
Inst Trans -3.73%
Short Ratio 5.32
Perf Half Y 339.66%
Book/sh 2.71
P/B 3.84
EPS next Y -1.98%
ROA -52.52%
Short Interest 1.75M
Perf Year 273.48%
Cash/sh 2.41
P/C 4.32
EPS next 5Y -
ROE -59.40%
52W Range 1.33 - 11.62
Perf YTD 46.14%
Dividend Est. -
P/FCF -
EPS past 5Y -63.20%
ROI -64.45%
52W High -10.33%
Beta 1.98
Dividend TTM -
Quick Ratio 9.15
Sales past 5Y 40.60%
Gross Margin -50.72%
52W Low 683.40%
ATR (14) 0.70
Dividend Ex-Date -
Current Ratio 9.15
EPS Y/Y TTM 16.70%
Oper. Margin -3327.44%
RSI (14) 53.37
Volatility 6.04% 6.97%
Employees 75
Debt/Eq 0.03
Sales Y/Y TTM 282.93%
Profit Margin -3133.63%
Recom 1.00
Target Price 15.75
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q 25.07%
Payout -
Rel Volume 0.77
Prev Close 10.66
Sales Surprise 265.93%
EPS Surprise 17.39%
Sales Q/Q 1856.14%
Earnings May 02 BMO
Avg Volume 328.57K
Price 10.42
SMA20 2.42%
SMA50 9.32%
SMA200 86.76%
Trades
Volume 254,361
Change -2.25%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-31-22 Initiated
BTIG Research
Buy
$12
Jun-01-22 Initiated
Citigroup
Buy
$13
May-02-22 Initiated
H.C. Wainwright
Buy
$28
Apr-14-21 Initiated
Berenberg
Buy
$47
Jan-11-21 Initiated
Evercore ISI
Outperform
Nov-03-20 Initiated
Needham
Buy
$34
Nov-03-20 Initiated
Cowen
Outperform
Nov-03-20 Initiated
Citigroup
Buy
$36
May-07-24 12:00PM
09:55AM
May-04-24 05:31AM
May-02-24 09:58PM
08:25AM
07:05AM
Loading…
07:05AM
Apr-09-24 04:05PM
Apr-01-24 07:00AM
Mar-04-24 07:00AM
Feb-29-24 04:05PM
Feb-26-24 07:00AM
Feb-14-24 05:06AM
Feb-13-24 06:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
08:00AM
Loading…
Dec-21-23 08:00AM
Dec-13-23 10:45AM
06:00AM
Dec-05-23 04:15PM
Nov-14-23 09:00AM
Nov-13-23 08:52AM
Nov-09-23 11:54PM
(Thomson Reuters StreetEvents) -23.21%
08:29AM
06:00AM
Nov-06-23 09:28AM
Nov-02-23 09:01AM
Oct-24-23 12:30PM
Aug-10-23 05:15PM
04:00PM
Jul-06-23 10:14AM
05:15PM
Loading…
May-25-23 05:15PM
May-09-23 05:15PM
04:00PM
Apr-03-23 07:00AM
Mar-21-23 11:50AM
Mar-16-23 08:31AM
Mar-01-23 07:00AM
Feb-27-23 10:46PM
Feb-23-23 04:30PM
Feb-16-23 07:00AM
Feb-09-23 06:01AM
Jan-27-23 08:34AM
Jan-09-23 07:00AM
Dec-13-22 06:51AM
Dec-01-22 09:55AM
Nov-11-22 05:51AM
Nov-08-22 04:30PM
Nov-07-22 08:00AM
Nov-04-22 11:55AM
Nov-03-22 08:30AM
Nov-01-22 04:30PM
Oct-12-22 10:04AM
(Simply Wall St.) +10.51%
Oct-05-22 04:30PM
Sep-01-22 04:15PM
Aug-20-22 08:41AM
Aug-11-22 07:00AM
Jul-06-22 07:20AM
(Simply Wall St.) +20.93%
May-28-22 08:05AM
May-13-22 08:50AM
May-12-22 07:00AM
May-06-22 09:00AM
May-05-22 09:14AM
Apr-08-22 04:55PM
Apr-05-22 05:00PM
Mar-21-22 12:00PM
Mar-15-22 07:00AM
Mar-09-22 08:21AM
Mar-02-22 08:39AM
Feb-09-22 05:00PM
Feb-02-22 01:38PM
Jan-27-22 09:21AM
Jan-05-22 08:30AM
Dec-13-21 01:57PM
Dec-03-21 07:59PM
Dec-02-21 03:40PM
07:17AM
Dec-01-21 10:45PM
Nov-29-21 10:30AM
Nov-28-21 07:58PM
Nov-26-21 12:39PM
Nov-25-21 11:23PM
05:00PM
Nov-23-21 05:44PM
Nov-22-21 01:00PM
09:47AM
Nov-21-21 11:20PM
Nov-18-21 04:01PM
Nov-15-21 11:32PM
Nov-11-21 05:55PM
Nov-10-21 12:30PM
Nov-09-21 01:19PM
08:00AM
08:00AM
Nov-04-21 07:00AM
Nov-03-21 05:19PM
Oct-28-21 04:30PM
Oct-12-21 11:11AM
Oct-01-21 09:56AM
Sep-01-21 04:30PM
Aug-11-21 04:30PM
Shattuck Labs, Inc. engages in the research and development of dual-sided fusion proteins used for medical treatment of cancer and autoimmune disease. It primarily focuses on Agonist Redirected Checkpoint (ARC) and Gamma Delta T Cell Engagers (GADLEN) platforms. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Stout Stephen See Remarks Mar 06 '24 Option Exercise 3.54 11,109 39,380 85,791 Mar 08 05:40 PM Stout Stephen See Remarks Mar 06 '24 Sale 10.53 16,004 168,522 74,437 Mar 08 05:40 PM Neill Andrew R Chief Financial Officer Jan 10 '24 Sale 10.00 25,000 250,000 173,446 Jan 16 04:35 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite